Staff Investigator - Turkson

夏威夷大学癌症中心正在请求为两(2)名工作人员提供部分支持，他们每人将专注于癌症中心主要感兴趣的战略研究/临床领域。 詹姆斯·特克森博士最近从莫菲特癌症中心和中佛罗里达大学招聘到夏威夷大学癌症中心，他将在癌症生物学计划内领导创建一个强有力的药物开发计划，目标是建立专注于转化研究的科学合作，让来自基础科学计划和临床合作伙伴的癌症中心成员参与进来。特克森博士在药物开发方面拥有丰富的经验，他花了十多年的时间设计和评估信号转导和转录激活因子-3(STAT-3)蛋白的小分子抑制剂。STAT-3介导多种基因的表达以响应细胞刺激，并在许多细胞过程中发挥关键作用，包括各种人类癌症的发生和发展。特克森博士发表了50多篇同行评议论文，并与人合著了该领域的4项已发布专利和8项临时专利和正在申请的专利。

The University of Hawaii Cancer Center is requesting partial support for two (2) Staff Investigators, each of whom will focus on a strategic research/clinical area of major interest to the Cancer Center. James Turkson, PhD, a recent recruit to the University of Hawaii Cancer Center from the Moffit Cancer Center and the University of Central Florida, will lead the creation of a robust drug development initiative within the Cancer Biology Program with the goal of building scientific collaborations focused on translational research involving Cancer Center members from both the basic science programs and our clinical partners. Dr. Turkson has extensive experience in drug development having spent more than a decade designing and evaluating small molecule inhibitors of the signaling transducer and activator of transcription-3 (STAT-3) protein. STAT-3 mediates the expression of a variety of genes in response to cell stimuli and plays a key role in many cellular processes, including the initiation and progression of various human cancers. Dr. Turkson has published over 50 peer reviewed papers and co-authored 4 issued patents and 8 provisional and pending patents in the field.